Bath & Body Works (NYSE:BBWI – Get Free Report) had its price target cut by research analysts at Morgan Stanley from $22.00 to $21.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley‘s target price suggests a potential upside of 10.91% from the company’s current price.
A number of other research firms also recently weighed in on BBWI. JPMorgan Chase & Co. raised their price target on shares of Bath & Body Works from $22.00 to $24.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. BMO Capital Markets started coverage on Bath & Body Works in a research report on Tuesday, September 8th. They issued a “market perform” rating and a $20.00 target price for the company. UBS Group upped their price objective on Bath & Body Works from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Friday, November 13th. Robert W. Baird dropped their price objective on shares of Bath & Body Works from $23.00 to $22.00 and set a “neutral” rating for the company in a report on Friday. Finally, Wells Fargo & Company raised their price target on shares of Bath & Body Works from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Thursday, October 29th. Three research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $22.40.
Check Out Our Latest Stock Report on Bath & Body Works
Bath & Body Works Stock Up 1.5%
BBWI opened at $18.93 on Friday. Bath & Body Works has a twelve month low of $14.27 and a twelve month high of $24.94. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of 4.93, a P/E/G ratio of 0.93 and a beta of 1.31. The company has a 50-day simple moving average of $19.24 and a 200 day simple moving average of $19.77.
Bath & Body Works (NYSE:BBWI – Get Free Report) last announced its quarterly earnings data on Thursday, November 19th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.14. Bath & Body Works had a net margin of 10.83% and a negative return on equity of 53.48%. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.55 billion. During the same period last year, the firm posted $0.37 earnings per share. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year. Bath & Body Works has set its Q4 2026 guidance at 1.410-1.610 EPS and its FY 2026 guidance at 2.600-2.800 EPS. Sell-side analysts anticipate that Bath & Body Works will post 2.74 EPS for the current fiscal year.
Institutional Investors Weigh In On Bath & Body Works
Several large investors have recently modified their holdings of BBWI. Bank of America Corp DE purchased a new position in Bath & Body Works in the 2nd quarter worth approximately $62,249,000. 1834 Investment Advisors Co. boosted its stake in shares of Bath & Body Works by 63.8% during the third quarter. 1834 Investment Advisors Co. now owns 316,246 shares of the company’s stock valued at $5,035,000 after purchasing an additional 123,222 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Bath & Body Works by 98.0% during the second quarter. Hsbc Holdings PLC now owns 588,941 shares of the company’s stock valued at $13,651,000 after purchasing an additional 291,470 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Bath & Body Works during the second quarter valued at approximately $46,706,000. Finally, BlackRock Inc. bought a new position in shares of Bath & Body Works in the second quarter worth approximately $449,065,000. Hedge funds and other institutional investors own 95.14% of the company’s stock.
Top Bath & Body Works Stories
Here are a few of the latest stories about BBWI:
- Positive Sentiment: Third-quarter adjusted earnings of $0.26 per share topped the $0.12 consensus estimate, while revenue of $1.58 billion also exceeded expectations. The company raised its full-year sales outlook, now projecting a decline of 3.4% to 2.1%. Q3 results and outlook
- Positive Sentiment: A new $500 million share-repurchase authorization may support shareholder returns. Management also cited progress in digital and wholesale sales, while its Fuel for Growth program is expected to generate $200 million in cost savings. Long-term investor takeaways
- Negative Sentiment: Investors face a weaker near-term outlook: fourth-quarter EPS guidance of $1.41–$1.61 is below the $1.72 analyst consensus, and the company warned of softer holiday sales. Third-quarter revenue was down about 1% year over year, and EPS was below the year-ago level. Holiday sales outlook
Bath & Body Works Company Profile
Bath & Body Works, Inc. is a specialty retailer focused on personal care and home fragrance products. Its offerings include body lotions, soaps, fragrances, hand sanitizers, candles and other home-fragrance items, sold under the Bath & Body Works and White Barn brands. The company serves customers through its stores and e-commerce platform in the United States and Canada, as well as through international franchise, license and wholesale partners. Bath & Body Works traces its roots to a store launched in 1990.
Recommended Stories
- Five stocks we like better than Bath & Body Works
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.
